ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2381

Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database
Abstract Number: 2382

Utility of Urinary Biomarkers to Predict Long-term Renal Outcomes in Lupus Nephritis
Abstract Number: 2383

Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience
Abstract Number: 2384

Performance and Concordance of Two Different Methods of Detecting the Commonest Autoantibodies in Systemic Lupus Erythematosus
Abstract Number: 2385

Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
Abstract Number: 2386

Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Abstract Number: 2387

Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus
Abstract Number: 2388

Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Abstract Number: 2389

Choroidal Thickness in Active Lupus Nephritis
Abstract Number: 2390

Anti-Sm Antibody Titers Vary During SLE Disease Course
Abstract Number: 2391

Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Abstract Number: 2392

Clinical Characteristics and Outcomes of Systemic Lupus Erythematosus When Accompanying Myositis: A Retrospective Real-Life Study
Abstract Number: 2393

Demographic Differences in Trends of Systemic Lupus Erythematosus In-hospital Patient Outcomes
Abstract Number: 2394

Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis
Abstract Number: 2395

Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].